Gene Medicine

Jul 10, 2024 | insights.bio | Steven Feldman |Gene Medicine |James Brady |Daniel Nguyen

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST The use of CAR-T cells as potent therapies for refractory B-cell and plasma cell malignancies poses an immense financial burden. It requires lengthy manufacturing times, especially for GMP-grade vector production. Non-viral gene delivery methods are therefore a desirable alternative, and the first non-viral cell therapy was recently FDA-approved.